NCT01421212已完成1 期
Study to Assess the Pharmacokinetics of Intravenous Nabi 5% Hepatitis B Immune Globulin Used in Combination With Lamivudine
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 20
- 主要终点
- Number of hepatitis B virus positive liver transplant recipients with no hepatitis B virus recurrence after liver transplantation.
研究概览
简要总结
The purpose of this study is to find the best monthly dose schedule for the new Hepatitis Immune Globulin (Boca HBVIg, a study drug) when used in combination with an antiviral agent Lamivudine after liver transplantation. Boca HBVIg will be given along with Lamivudine to prevent hepatitis B reinfection following liver transplantation in patients with end stage liver failure due to hepatitis B infection.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Be 18 years old or greater, either male or female, of any ethnic background.
- •Be positive for HBsAg. Patients may be either positive or negative for anti-HDV, HBeAg, and HBV DNA (non-PCR assay).
- •Be diagnosed with HBV-induced liver disease including either:
- •HBsAg positive cirrhosis, or
- •HBsAg positive and presence of hepatocellular carcinoma (HCC) with no evidence of vascular invasion or extrahepatic spread, and either:
- •a single tumor no larger than 5 cm in diameter, or
- •no more than three tumors, the largest of which is no greater than 3 cm in diameter.
- •Have received at least one dose of Lamivudine 100 mgs po qd prior to transplantation.
- •Fulfill UNOS minimal listing criteria.
- •Have received approval for liver transplantation at the respective participating center and are listed as Status 2 or 3 and felt to be within three months of liver transplantation.
- •If requiring retransplantation for primary graft nonfunction or hepatic artery thrombosis, retransplantation must take place within the first four weeks of the initial transplant with no evidence of recurrent hepatitis B.
- •Be able and willing to give written informed consent. In patients with Grade 3 or 4 hepatic encephalopathy, a legal guardian must be available to provide consent. In the case of a minor, a parent or guardian must provide consent.
- •If a woman of childbearing potential, have a negative serum beta HCG pregnancy test within 14 days prior to starting Lamivudine therapy and within 14 days prior to transplant and agree to practice contraception during the study (a total of 36 weeks).
排除标准
- •Eligible patients must not:
- •Require retransplantation for recurrent hepatitis B.
- •Have chronic hepatitis B liver disease with a history of breakthrough infection on Lamivudine
- •Have other causes of liver disease including chronic hepatitis C.
- •Have HCC and do not meet Inclusion Criterion #3, or who require systemic chemotherapy.
- •Be seropositive for HIV infection.
- •Be using experimental devices or receiving experimental drugs.
- •Be participating in any other clinical treatment trial with an investigational drug within 30 days prior to liver transplantation or plan to receive another investigational drug during this study.
结局指标
主要结局
Number of hepatitis B virus positive liver transplant recipients with no hepatitis B virus recurrence after liver transplantation.
Number of participants who maintain a protective trough titer of anti hepatitis B antibodies beginning at 12 weeks post liver transplantation.
次要结局
- Change in anti hepatitis B antibodies levels with administration of Boca hepatitis B immune globulin concomitantly with Lamivudine.
研究者
研究点 (20)
Loading locations...
相似试验
已完成
3 期
A Clinical Study of Intravenous ImmunoglobulinImmunologic Deficiency SyndromesNCT00468273FFF Enterprises57
已完成
不适用
Study on the Pharmacokinetic Characteristics of I.V. Hepabig Injection Used for Prevention of Hepatitis B Relapse After Liver TransplantationChronic Hepatitis BLiver CirrhosisNCT02125071Dong-Gu Kim20
已完成
1 期
A Single Ascending Dose Study of Soluble Ferric Pyrophosphate Administered Intravenously in Healthy Volunteers.Kidney Failure, Chronic Therapy; HemodialysisNCT01920854Rockwell Medical Technologies, Inc.48
已完成
不适用
Clinical Decision Support Tool for Vancomycin Dosing in ChildrenGram-Positive Bacterial InfectionsVancomycinPharmacokineticsPharmacodynamicsNCT04911270University of Maryland, Baltimore75
已完成
1 期
Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without BevacizumabAdvanced CancersNCT01213238M.D. Anderson Cancer Center116